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Abstract
Ankle-brachial pressure index (ABPI) is commonly measured in people referred to vascular
specialists. This study aimed to assess the association of high ABPI (� 1.4) with cardiovascu-
lar events in people with peripheral artery disease (PAD). 1533 participants with PAD diag-
nosed by a vascular specialist were prospectively recruited from four out-patient clinics in
Australia. ABPI was measured at recruitment and the occurrence of myocardial infarction
(MI), stroke or cardiovascular death (major cardiovascular events; MACE) and any amputa-
tion were recorded over a median (inter-quartile range) follow-up of 3.3 (1.0–7.1) years. The
association of high, compared to normal, low (0.5–0.9) or very low (<0.5), ABPI with clinical
events was estimated using Cox proportional hazard analyses, adjusting for traditional risk
factors and reported as hazard ratio with 95% confidence intervals. 596 (38.9%), 676 (44.1%),
157 (10.2%) and 104 (6.8%) participants had normal, low, very low and high ABPI, respec-
tively. Participants with high ABPI had increased risk of MACE, MI and death by comparison
to those with either normal ABPI [1.69 (1.07, 2.65), 1.93 (1.07, 3.46) and 1.67 (1.09, 2.56)] or
either low or very low ABPI [1.51 (1.02, 2.23), 1.92 (1.16, 3.19) and 1.47 (1.02, 2.14)] after
adjusting for other risk factors. Findings were similar in a sensitivity analysis excluding people
with ABPI only measured in one leg (n = 120). Participants with high ABPI also had an
increased risk of MACE and MI compared to those with very low ABPI alone. High ABPI is a
strong indicator of excess risk of cardiovascular events amongst people with PAD.
Introduction
Ankle-brachial pressure index (ABPI), the ratio between systolic pressure at the ankle and
arm, is recommended by current guidelines as a diagnostic test for peripheral artery disease
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(PAD) [1, 2]. Low ABPI (usually defined as�0.9) is a strong predictor of increased risk of
myocardial infarction (MI), stroke and cardiovascular death and has been reported to improve
cardiovascular event prediction over conventional models, such as the Framingham risk score,
alone [3–6].
Population studies report that about 3 to 5% of people have an abnormally high ABPI, com-
monly defined as�1.4 [3, 7–9]. In these instances, the test is typically concluded to not be able
to provide diagnostic information about PAD and it is currently unclear how such patients
should be managed [1, 2, 10]. Since high ABPI indicates arterial calcification, an established
predictor of cardiovascular events, it is likely that its identification has important implications
for prognosis and treatment [11]. In previous studies high ABPI has been associated with
increased risk of cardiovascular events in some but not all studies [3, 7–9, 12–14]. Mostly these
studies have investigated community populations that have a low prevalence of cardiovascular
disease [7–9, 12, 13]. A recent meta-analysis suggested that high ABPI may also be an impor-
tant prognostic indicator for cardiovascular events in people with established cardiovascular
disease [13].
PAD includes a group of occlusive and aneurysmal diseases, such as lower limb artery
occlusion, abdominal aortic aneurysm (AAA) and carotid artery disease, resulting from nar-
rowing and occlusion of the peripheral arteries, which is associated with a particularly high
rate of major cardiovascular events (MACE) [15]. The association of high ABPI with cardio-
vascular events in this high-risk population has not been previously established. This study
aimed to clarify the risk factors and prognostic implications of a high ABPI in a hospital popu-
lation with established vascular disease. A heterogeneous group of people with established
PAD attending vascular laboratories at the included sites were studied. Unlike prior studies,
participants with high ABPI were separately compared to those with normal or low ABPI in
order to identify the unique prognostic significance of a high ABPI within a population with
PAD.
This study had two aims, firstly, to identify risk factors associated with high ABPI, and sec-
ondly, to compare the risk of MACE, amputation and all-cause mortality for PAD patients
with high ABPI, to those of PAD patients with normal or low ABPI.
Methods
Study design and participants
This investigation was designed as part of an ongoing prospective cohort study that com-
menced in 2002 [16, 17]. Participants with PAD were recruited from out-patient clinics at two
public (Townsville University and Royal Brisbane and Women’s Hospitals) and two private
(the Mater Hospital Townsville and Gosford Vascular Services) vascular departments between
February 2002 and November 2019. Participants with the following types of PAD were eligible
for inclusion: a) Asymptomatic carotid artery stenosis defined as the presence of�50% steno-
sis or occlusion of at least one carotid artery identified by carotid duplex but the absence of
physician confirmed symptoms of focal transient ischemic attack, amaurosis fugax or stroke
[18]; b) Intermittent claudication, with clinical or imaging evidence of lower limb athero-
thrombosis, but no symptoms of rest pain or tissue loss [19]; c) Aneurysm of the aorta or
peripheral arteries defined as previously reported [16, 20]; d) Symptomatic carotid artery ste-
nosis: Defined as the presence of�50% stenosis or occlusion of at least one carotid artery iden-
tified with carotid duplex with the presence of physician confirmed symptoms of focal
transient ischemic attack, amaurosis fugax or stroke [18]; e) Rest pain or tissue loss of the
lower limb [19]. Written informed consent was obtained from all participants upon entry into
the study. Patients in whom ABPI could not be measured at the time of recruitment were
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excluded from the study. The study was performed in accordance with the declaration of Hel-
sinki and ethical approval was granted from Townsville Hospital and Health Services Ethics
Committee.
Definitions of risk factors and medications recorded
Age and sex were recorded at recruitment. Current smoking was defined as smoking within
the last month, past smoking as having given up regularly smoking more than one month ago
and never smoking as no prior history of smoking [16, 21]. Hypertension, diabetes and stroke
were defined by a documented past history of diagnosis of these conditions [16, 21]. Ischemic
heart disease (IHD) was defined as a documented history of MI, angina or previous treatment
of IHD [21]. End-stage renal failure was defined by the requirement for renal dialysis. All pre-
scribed medications including anti-platelet drugs, anti-coagulants, statins, fibrates, angiotensin
converting enzyme (ACE) inhibitors, angiotensin receptor blockers, calcium channel blockers,
furosemide, insulin, metformin and other hypoglycaemic medications were recorded at the
time of recruitment.
Measurement of ABPI
ABPI was measured by a trained sonographer or researcher within a vascular laboratory. Par-
ticipants rested supine for 10 minutes and ABPI was assessed using a 5 MHz Doppler probe
and sphygmomanometer cuff, with a width at least 40% of the limb circumference, according
to guidelines [10, 22]. ABPI was reported in each leg as the maximum of dorsalis pedis or pos-
terior tibial divided by the maximum brachial pressure on either side. Subsequently ABPI was
classified as normal (0.91–1.39 in both legs), high (�1.4 in either leg), low (0.5–0.9 in at least
one leg but not�1.4 in either leg) or very low (<0.5 in at least one leg but not�1.4 in either
leg) [10].
Definition and assessment of outcomes
Participants were followed up as part of normal care according to local clinical policies. Partici-
pants were offered at least one follow-up appointment and usually followed up annually. Out-
come data were recorded during clinical reviews on case report forms. Hospital charts and
electronic records were also reviewed by a vascular specialist. Outcome data were also obtained
from linked hospital admission records using the Queensland hospital admitted patient data
collection as previously described [16, 17, 23, 24]. This data collection is regularly audited to
minimize inaccuracies [25]. The primary outcome of this study was MACE incidence, defined
as the first occurrence of MI, stroke or cardiovascular death. Secondary outcomes included the
individual incidence of MI or stroke alone, any lower limb amputation, major lower limb
amputation (defined as above the ankle) alone and all-cause mortality.
Sample size
It was aimed to have adequate power to test the hypothesis that high, compared to normal or
low, ABPI was associated with an increased hazard of MACE. Prior studies suggest that
MACE is common in people with PAD occurring in between 30 and 40% during short term
follow-up [16, 19, 23, 26]. Monte-Carlo simulations suggest that a multivariable regression
model is powered sufficiently when 10 outcome events per degree of freedom of the predictor
variables are observed [27]. It was estimated that the two year incidence of MACE would be
approximately 30% and planned to adjust for 13 variables, some with multiple degrees of free-
dom, including age, sex, presentation (asymptomatic carotid stenosis, intermittent
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claudication, aneurysm of the aorta or peripheral arteries, symptomatic carotid stenosis or tis-
sue loss or rest pain), current smoking, diabetes, hypertension, IHD, stroke, end-stage renal
failure, prescription of statins, anti-coagulants, anti-platelets and furosemide. Based on these
estimates it was felt that a sample size of about 1500 participants would be well powered to test
the main hypothesis through expected a total of over 400 primary outcome events, i.e. well in
excess of the 10 outcome events per variable in the Cox proportional hazard analysis. This was
expected to allow appropriate power for analyses limited to sub-groups of participants as well.
Data analysis
The characteristics of participants were compared in relation to their ABPI group (normal,
low, very low or high). Continuous data were not normally distributed, as confirmed using the
Shapiro Wilk test and were presented as median and inter-quartile range (IQR) and compared
between groups using the Kruskal-Wallis test. Categorical variables were compared using
Pearson’s chi squared test. Kaplan Meier analysis was used to calculate the observed incidence
of clinical events and the log rank test to statistically compare incidence rates. Cox propor-
tional hazard analyses assessed the association of high ABPI, compared to normal or low or
very low ABPI combined (�0.90), with events adjusted for other risk factors including age,
sex, presentation (asymptomatic carotid stenosis, intermittent claudication, AAA, symptom-
atic carotid stenosis or tissue loss or rest pain), current smoking, diabetes, hypertension, IHD,
stroke, end-stage renal failure, prescription of statins, anti-coagulants, anti-platelets and furo-
semide. A further analysis was performed to examine the association of high ABPI with events
when comparing separately to people with low (0.50–0.90) or very low (<0.50) ABPI. A sensi-
tivity analysis was performed to examine the effect of excluding people in whom ABPI was
only measured in one leg on the main Cox proportional hazard analysis findings. All adjusted
analyses were stratified by presenting complaint and end-stage renal failure in order to comply
with model assumptions. Participants were censored at the time of their first relevant event, or
at the date of last follow-up if no event was experienced. All presented model conformed to the
proportional hazards assumption demonstrated by a global p-value >0.05. Hazard ratios and
95% confidence intervals (CI) were presented. The total number of events experienced by the
patients in different ABPI groups was also quantified. Participants were not censored at the
time of first event for these analyses. Data were analysed using the SPSS v 25 (IBM, Armonk,
NY) and R software packages. P values of<0.05 were accepted to be significant for all analyses.
Results
Risk factors associated with high ABPI
Of a total of 1533 participants that had ABPI measured in both (n = 1413) or one leg (n = 120;
54 left only; 66 right only), 104 (6.8%) had a high ABPI (Table 1). Sex, presenting problem, risk
factors and medications varied significantly according to ABPI group (see Table 1).
Association of high, compared with normal, ABPI with adverse events
Participants were followed for a median of 3.3 (1.0–7.1) years. During this period 389 (25.4%)
participants’ died and 172 (11.2%), 78 (5.1%) and 76 (5.0%) had at least one MI, stroke and
amputation, respectively. 142 participants (9.3%) did not attend any follow-up appointments
and were considered lost to follow-up. Participants with a high ABPI had a higher incidence of
MACE, MI, any amputation and death than those with a normal ABPI both before and after
adjustment for other risk factors (Table 2 and Fig 1). High, compared to normal, ABPI was
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associated with a higher incidence of major amputation in before but not after adjusting for
other risk factors (Table 2 and Fig 1).
Association of high, compared with low, ABPI with adverse events
Participants with a high ABPI had a higher risk of MACE, MI and death than those with low
or very low ABPI combined (�0.90), before and after adjustment for other risk factors
(Table 2 and Fig 1). Participants with a high ABPI had a higher risk of any amputation than
those with low or very low ABPI combined (�0.90), before but not after adjustment for other
risk factors (Table 2 and Fig 1). Participants with high ABPI had a higher risk of MI, any
amputation and death, than those with low ABPI (0.50–0.90), both before and after adjusting
for other risk factors (Table 3 and Fig 1). Participants with high ABPI had a higher risk of
MACE than those with low ABPI (0.50–0.90), before but not after adjusting for other risk fac-
tors (Table 3 and Fig 1). Participants with high ABPI had a higher risk of MACE and MI, but
Table 1. Risk factors and medications in relation to ankle-brachial pressure index amongst people with peripheral artery disease.
Risk factor Ankle-brachial pressure index
Normal Low Very low High P value
Participants 596 676 157 104
Age (years) 70 (63–76) 69 (62–75) 70 (64–75) 69 (62–76) 0.668
Male 461 (77.4) 511 (75.6) 104 (66.2) 77 (74.0) 0.039
Presenting problem <0.001
Asymptomatic carotid artery stenosis 38 (6.4) 25 (3.7) 3 (1.9) 3 (2.9)
Intermittent claudication 123 (20.6) 370 (54.7) 85 (54.1) 50 (48.1)
Aortic or peripheral aneurysm 297 (49.8) 168 (24.9) 24 (15.3) 19 (18.3)
Symptomatic carotid artery stenosis 38 (6.4) 29 (4.3) 16 (10.2) 8 (7.7)
Tissue loss or rest pain 100 (16.8) 84 (12.4) 29 (18.5) 24 (23.1)
Documented past history
Current smoking 150 (25.2) 241 (35.7) 66 (42.0) 13 (12.5) <0.001
Past smoking 309 (51.8) 369 (54.6) 76 (42.0) 71 (68.3)
Hypertension 427 (71.6) 496 (73.4) 134 (85.4) 87 (83.7) 0.001
Diabetes 216 (36.2) 209 (30.9) 50 (31.8) 58 (55.8) <0.001
Ischemic heart disease 255 (42.8) 299 (44.2) 73 (46.5) 67 (64.4) 0.001
Stroke 48 (8.1) 67 (9.9) 21 (13.4) 19 (18.3) 0.007
End-stage renal failure 5 (0.8) 1 (0.2) 1 (0.6) 6 (5.8) <0.001
Medication
Any anti-platelet 369 (61.9) 490 (72.5) 131 (83.4) 74 (71.2) <0.001
Any anti-coagulant 54 (9.1) 42 (6.2) 12 (7.6) 16 (15.4) 0.010
Statin 406 (68.1) 460 (68.0) 116 (73.9) 80 (76.9) 0.153
Fibrate 22 (3.7) 24 (3.6) 7 (4.5) 2 (1.9) 0.753
Angiotensin converting enzyme inhibitor 207 (34.7) 270 (39.9) 69 (43.9) 49 (47.1) 0.025
Angiotensin receptor blocker 153 (25.7) 161 (23.8) 44 (28.0) 26 (25.0) 0.703
Calcium channel blocker 152 (25.5) 210 (31.1) 61 (38.9) 35 (33.7) 0.005
Furosemide 41 (6.9) 62 (9.2) 19 (12.1) 18 (17.3) 0.003
Metformin 148 (24.8) 126 (18.6) 31 (19.7) 36 (34.6) 0.001
Insulin 51 (8.6) 45 (6.7) 13 (8.3) 22 (21.2) <0.001
Any other hypoglycemic 79 (13.3) 89 (13.2) 16 (10.2) 31 (29.8) <0.001
Shown are number (percentage) or median (inter-quartile range). Ankle-brachial pressure index group: 0.91–1.39 = normal; 0.50–0.90 = low; <0.50 = very low;
�1.40 = high.
https://doi.org/10.1371/journal.pone.0242228.t001
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not stroke, amputation or death, than those with very low ABPI (<0.50), both before and after
adjusting for other risk factors (Table 3 and Fig 1).
Sensitivity analysis
In analyses excluding the 120 participants that had ABPI only measured in one leg, the only
notable change from the main analysis was that the risk of MI alone was no longer significantly
higher in participants with high compared to normal ABPI, after adjusting for other risk fac-
tors (Table 4).
Association of high ABPI with total clinical events
Many participants had multiple clinical events. Table 5 illustrates the total number of clinical
events and the number of participants that had the events in relation to ABPI group. There
was a marked excess of total MACE, MI and amputation in participants with high ABPI.
Table 2. Association of high ankle-brachial pressure index with adverse events.
Events Compared to participants with normal ABPI Compared to participants with low or very low ABPI
Models Unadjusted Adjusted� Unadjusted Adjusted�
MACE 2.15 (1.45, 3.19) 1.69 (1.07, 2.65) 1.75 (1.21, 2.52) 1.51 (1.02, 2.23)
Myocardial infarction 2.18 (1.30, 3.64) 1.93 (1.07, 3.46) 2.10 (1.29, 3.41) 1.92 (1.16, 3.19)
Stroke 1.48 (0.64, 3.41) 1.19 (0.47, 3.05) 1.38 (0.62, 3.07) 1.59 (0.68, 3.71)
Any amputation 4.45 (2.16, 9.17) 3.51 (1.47, 8.39) 2.77 (1.49, 5.14) 1.84 (0.92, 3.69)
Major amputation 2.99 (1.00, 8.92) 3.24 (0.72, 14.62) 2.06 (0.78, 5.46) 1.65 (0.51, 5.28)
All-cause mortality 2.13 (1.47, 3.08) 1.67 (1.09, 2.56) 1.56 (1.11, 2.20) 1.47 (1.02, 2.14)
Shown are hazard ratios (95% confidence intervals) for events in comparison to participants with normal or low ABPI. MACE = Major adverse cardiovascular events.
� Adjusted for age, sex, presenting problem, current smoking, diabetes, hypertension, ischemic heart disease, stroke, end-stage renal failure, prescription of statins, anti-
coagulants, anti-platelet and furosemide medications.
https://doi.org/10.1371/journal.pone.0242228.t002
Fig 1. Incidence of major cardiovascular events. (a), any amputation (b), death (c), myocardial infarction (d) and major amputation (e) in
participants with high (light blue line) compared to those with normal (dark blue line), low (red line) or very low (green line) ankle-brachial
pressure index. � Denotes statistical comparisons between participants with high and normal ankle-brachial pressure index. + Denotes statistical
comparisons between participants with high and low ankle-brachial pressure index. kDenotes statistical comparisons between participants with
high and very low ankle-brachial pressure index.
https://doi.org/10.1371/journal.pone.0242228.g001
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There were, for example, a total of 43 MIs in 104 participants with high ABPI compared with
123 in 676 participants with low ABPI (Table 5).
Discussion
It commonly believed that an important weakness of the ABPI test is its non-diagnostic value
in people with incompressible tibial arteries [10]. This study demonstrates that the finding of a
high ABPI, amongst people with PAD, provides important prognostic information. High
ABPI was independently associated with an increased hazard of MACE, MI and death. Strik-
ingly, the increased hazard of these important clinical events was found in comparison to par-
ticipants with low ABPI, as well as compared to those with normal ABPI. This demonstrates
the clear clinical value of identifying a high ABPI in people with PAD.
In the current study, about 7% of participants had an ABPI�1.4, a rate higher than
reported in community populations [3, 7–9]. Participants with high ABPI had different risk
factors to those with normal or low ABPI, including high prevalence of diabetes, in keeping
with its accepted role in promoting arterial calcification [28]. They also had a relatively low fre-
quency of current smoking by comparison to participants with low ABPI.
Prior studies of community populations have shown independent associations of high
ABPI with cardiovascular events in some but not all populations [3, 5, 7–10, 12–14]. In the cur-
rent study participants were recruited from hospital out-patient clinics and had PAD diag-
nosed by a vascular specialist. This population included a large number of people with low
Table 3. Association of high ankle-brachial pressure index with adverse events.
Events Compared to participants with low ABPI Compared to participants with very low ABPI
Models Unadjusted Adjusted� Unadjusted Adjusted�
MACE 1.74 (1.20, 2.52) 1.46 (0.98, 2.19) 1.82 (1.14, 2.92) 1.88 (1.11, 3.21)
Myocardial infarction 2.07 (1.27, 3.40) 1.94 (1.15, 3.29) 2.21 (1.16, 4.22) 2.43 (1.18, 4.97)
Stroke 1.45 (0.64, 3.27) 1.55 (0.64, 3.78) 1.14 (0.44, 2.97) 1.31 (0.44, 3.89)
Any amputation 3.09 (1.62, 5.89) 2.19 (1.06, 4.55) 1.91 (0.88, 4.15) 1.20 (0.47, 3.09)
Major amputation 2.76 (0.98, 7.74) 2.60 (0.73, 9.26) 1.01 (0.34, 3.03) 0.91 (0.23, 3.65)
All-cause mortality 1.67 (1.18, 2.37) 1.54 (1.04, 2.26) 1.26 (0.83, 1.90) 1.31 (0.82, 2.11)
Shown are hazard ratios (95% confidence intervals) for events in comparison to participants with normal or low ABPI. MACE = Major adverse cardiovascular events.
� Adjusted for age, sex, presenting problem, current smoking, diabetes, hypertension, ischemic heart disease, stroke, end-stage renal failure, prescription of statins, anti-
coagulants, anti-platelet and furosemide medications.
https://doi.org/10.1371/journal.pone.0242228.t003
Table 4. Association of high ankle-brachial pressure index with clinical events excluding participants in whom ABPI was only measured in one leg.
Events Compared to participants with normal ABPI Compared to participants with low or very low ABPI
Models Unadjusted Adjusted� Unadjusted Adjusted�
MACE 2.25 (1.50, 3.38) 1.68 (1.04, 2.71) 1.85 (1.27, 2.68) 1.68 (1.12, 2.51)
Myocardial infarction 2.22 (1.32, 3.74) 1.78 (0.97, 3.24) 2.16 (1.33, 3.51) 2.15 (1.29, 3.60)
Stroke 1.58 (0.67, 3.70) 1.24 (0.46, 3.32) 1.52 (0.68, 3.40) 1.66 (0.70, 3.92)
Any amputation 4.20 (1.84, 9.58) 3.50 (1.26, 9.69) 2.35 (1.17, 4.71) 1.89 (0.87, 4.11)
Major amputation 2.49 (0.62, 9.96) 1.81 (0.27, 11.90) 1.35 (0.40, 4.55) 1.44 (0.38, 5.53)
All-cause mortality 2.20 (1.48, 3.28) 1.72 (1.08, 2.75) 1.52 (1.06, 2.19) 1.52 (1.02, 2.25)
Shown are hazard ratios (95% confidence intervals) for events in comparison to participants with normal or low ABPI. MACE = Major adverse cardiovascular events.
� Adjusted for age, sex, presenting problem, current smoking, diabetes, hypertension, ischemic heart disease, stroke, end-stage renal failure, prescription of statins, anti-
coagulants, anti-platelet and furosemide medications.
https://doi.org/10.1371/journal.pone.0242228.t004
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ABPI which allowed comparison with that high risk group, unlike prior studies which have
simply compared to people with normal ABPI [3, 5, 7–10, 12–14]. Within this PAD popula-
tion, high ABPI strongly and independently predicted the key clinical events of MACE, MI
and death. After adjusting for other risk factors, participants with high ABPI had an approxi-
mate 2-fold increased risk of MI compared with those with low or very low ABPI combined.
This finding was similar when comparing participants with high ABPI to those with very low
ABPI alone.
Despite the high incidence of events in participants with high ABPI, about 25% were not
prescribed a statin and 29% not receiving any anti-platelet medication. Given the very high
rate of cardiovascular events in people with high ABPI, it is likely they would substantially ben-
efit from intensive medical management. High ABPI might identify people, for example, in
whom it is highly beneficial and cost-effective to intensively lower low density lipoprotein-
cholesterol with recently introduced Proprotein Convertase Subtilisin/kexin type 9 (PCSK9)
Inhibitions [29].
The results of this study should be interpreted acknowledging its strengths and weakness.
The study includes a heterogeneous population with multiple different presentations recruited
from hospital out-patient clinics and thus is likely to be generalizable to similar heterogeneous
populations that have been referred to vascular surgery out-patient clinics. The findings may
not be relatable to populations recruited from the community or to homogenous presentations
of PAD. While high ABPI was independently associated with cardiovascular events, it is possi-
ble that risk factors that were not measured, such as renal function, thrombophilia or previous
peripheral revascularization, and therefore were unable to be adjusted for may have contrib-
uted to this association. High ABPI is a measure of arterial calcification, a recognized predictor
of clinical events, and adjustment for this may have influenced the associations demonstrated
[11]. ABPI is, however, more straightforward and cheaper to measure than arterial calcifica-
tion. In addition, clinical outcome data were extracted from patient medical records, rather
than an independent adjudication committee and the potential that some clinical events may
have been missed, or misclassified cannot be excluded. Also whilst analyses were adjusted to
account for potentially important differences in medication use between the groups at the time
of enrolment, changes in medications during follow-up were not recorded and could not be
Table 5. Total clinical events in relation to ankle-brachial pressure index.
Normal Low Very low High
Participants 596 676 157 104
Follow-up (years) 2.7 (0.6–6.4) 3.4 (1.3–7.6) 4.4 (1.9–7.5) 3.2 (1.0–7.0)
Total number of MACE 141 257 70 69
Number of participants that the MACE events occurred in 95 (15.9) 161 (23.8) 40 (25.5) 34 (32.7)
Total myocardial infarction events 71 123 29 43
Number of participants that the myocardial infarction events occurred in 55 (9.2) 78 (11.5) 19 (12.1) 20 (19.2)
Total stroke events 30 39 21 8
Number of participants that the stroke events occurred in 25 (4.2) 34 (5.0) 12 (7.6) 7 (6.7)
Total amputations 33 52 21 34
Number of participants that the amputations occurred in 17 (2.9) 33 (4.9) 13 (8.3) 13 (12.5)
Total major amputations 16 14 14 8
Number of participants that the major amputations occurred in 9 (1.5) 13 (1.9) 9 (5.7) 5 (4.8)
Shown are total number of events and number (percentage) of participants that had the events from each ABPI group.
MACE = Major adverse cardiovascular events.
https://doi.org/10.1371/journal.pone.0242228.t005
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accounted for. Finally a number of participants were lost to follow-up which may have affected
findings.
In conclusion, this study demonstrates that amongst people with diagnosed PAD, a high
ABPI is an important indicator of high risk of cardiovascular events, including MACE, MI and
death. Importantly the risk of events was higher than for people with low ABPI. These findings
suggest that people with high ABPI should be considered for intensive medical treatment to
lower their risk of clinically important events.
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